Introduction to Head and Neck Cancer

  • Panagiota Economopoulou
  • Amanda K. PsyrriEmail author


Squamous cell cancers of the head and neck (HNSCC) comprise a diverse group of malignancies that include tobacco-related tumors in addition to an increasing number of human papillomavirus (HPV)-associated cancers. HPV-associated oropharynx cancer encompasses a distinct biological and clinical entity; it has a more favorable prognosis and may require less intensive treatment. The majority of HNSCC patients present with locally advanced disease for which multimodality therapeutic approach is employed. Despite advances in multimodality treatment, the 5-year progression-free survival rate of patients with HPV-negative locally advanced HNSCC does not exceed 40–50%, and survival rates for recurrent or metastatic (R/M) disease remain very dismal.


  1. 1.
    Al-Sarraf M (2002) Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 9:387–399CrossRefGoogle Scholar
  2. 2.
    Weinberger PM, Yu Z, Haffty BG et al (2006) Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736–747CrossRefGoogle Scholar
  3. 3.
    Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefGoogle Scholar
  4. 4.
    Arens AI, Troost EG, Schinagl D et al (2011) FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging 55:521–528PubMedGoogle Scholar
  5. 5.
    Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98CrossRefGoogle Scholar
  6. 6.
    El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838–847CrossRefGoogle Scholar
  7. 7.
    Munro AJ (1995) An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71:83–91CrossRefGoogle Scholar
  8. 8.
    Passero VA, Branstetter BF, Shuai Y et al (2010) Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol 21:2278–2283CrossRefGoogle Scholar
  9. 9.
    Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578CrossRefGoogle Scholar
  10. 10.
    Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116–1127CrossRefGoogle Scholar
  11. 11.
    Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 221:632Google Scholar
  12. 12.
    Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Internal Medicine-Section of Medical OncologyAttikon University HospitalAthensGreece

Personalised recommendations